Abstract
Cardiovascular effects of the tetracyclic antidepressant drug mianserin were examined in a prospective study including ten elderly depressed patients (age 60-77 years). During 1 week on placebo and 5 weeks on mianserin, 60 mg per day, orthostatic blood pressure testing, recording of standard electrocardiogram, 24-h electrocardiographic recording and systolic time intervals were carried out along with frequent monitoring of plasma levels of mianserin (13-57 micrograms/l) and the primary metabolite desmethylmianserin (7-27 micrograms/l). Mianserin caused a significant increase in orthostatic systolic blood pressure drop, and this correlated well with the plasma mianserin levels (rs = 0.70). There were no significant changes in supine blood pressure or in orthostatic changes in heart rate. No cardiac conduction disturbances or arrhythmias were provoked, but mianserin caused changes in systolic time intervals indicating impairment of left ventricular contractility and performance. Like tricyclic antidepressants mianserin should thus be used with caution in patients with latent or overt cardiovascular disease.
References
Mar 3, 1979·Lancet·A H GlassmanM Davies
Sep 17, 1976·Psychopharmacology·K GhoseP Turner
Nov 1, 1979·Circulation·E G GiardinaS J Kantor
Oct 1, 1979·Postgraduate Medical Journal·C D BurgessP Turner
Jan 16, 1978·JAMA : the Journal of the American Medical Association·D BurckhardtH Neubauer
Jan 1, 1978·British Journal of Clinical Pharmacology·E A SotaniemiJ Ahlqvist
Sep 1, 1978·British Heart Journal·D J Taylor, R A Braithwaite
Feb 2, 1976·Psychopharmacologia·P Kragh-SorensenE F Hvidberg
Aug 1, 1973·The Journal of Pharmacy and Pharmacology·A Nagy, L Treiber
Aug 1, 1972·The British Journal of Psychiatry : the Journal of Mental Science·C GurneyK Schapira
Feb 1, 1968·Circulation·A M WeisslerC D Schoenfeld
Apr 1, 1969·The American Journal of Cardiology·A M WeisslerC D Schoenfeld
Dec 1, 1967·The British Journal of Social and Clinical Psychology·M Hamilton
Sep 1, 1983·Clinical and Experimental Pharmacology & Physiology·J R NielsenL F Gram
Mar 26, 1981·European Journal of Pharmacology·H Hall, S O Ogren
Jan 1, 1980·Endocrine Reviews·J W Rowe, B R Troen
Jan 1, 1981·Psychopharmacology·P ThayssenL F Gram
Jun 1, 1980·Clinical Pharmacology and Therapeutics·R C VeithR Bielski
Aug 1, 1980·The American Journal of Psychiatry·M V Rudorfer, R C Young
Citations
Jan 1, 1985·Psychopharmacology·P ChristensenP Kragh-Sørensen
Jan 1, 1985·Psychopharmacology·C B KristensenP Kragh-Sørensen
Jan 1, 1985·Psychopharmacology·P ChristensenL F Gram
May 1, 1985·Journal of Affective Disorders·P ChristensenH Y Thomsen
Apr 15, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Yoram BarakRonit Weizman
Jan 1, 1989·Psychological Medicine. Monograph Supplement·S J WarringtonM Lader
Sep 6, 2002·Epidemiologia e psichiatria sociale·Riccardo Torta, Angela Scalabrino
Feb 16, 1991·BMJ : British Medical Journal·W E HaefeliA Scholer
May 6, 2006·Cardiology·S E HaineC J Vrints
Jun 26, 2009·Drugs & Aging·Adam DarowskiDavid J Chambers
Oct 1, 2005·Nordic Journal of Psychiatry·Kurt Bjerregaard Bjerregaard Stage, UNKNOWN Danish University Antidepressant Group
Sep 1, 1991·Human & Experimental Toxicology·B CarconeJ Descotes
Jan 1, 1985·Acta Psychiatrica Scandinavica. Supplementum·R M Pinder
Oct 7, 2017·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Seetal DoddMichael Berk
Jun 28, 2002·Acta Psychiatrica Scandinavica·K B StageUNKNOWN Danish University Antidepressant Group
Aug 21, 2021·Frontiers in Cardiovascular Medicine·Anna CalviAderville Cabassi